YU45202A - Novi oblici natrijum pravastatina - Google Patents

Novi oblici natrijum pravastatina

Info

Publication number
YU45202A
YU45202A YU45202A YUP45202A YU45202A YU 45202 A YU45202 A YU 45202A YU 45202 A YU45202 A YU 45202A YU P45202 A YUP45202 A YU P45202A YU 45202 A YU45202 A YU 45202A
Authority
YU
Yugoslavia
Prior art keywords
pravastatin sodium
forms
novel forms
crystallization
new
Prior art date
Application number
YU45202A
Other languages
English (en)
Inventor
Vilmos Keri
Csaba Szabo
Edit Nagyne Arvai
Judith Aronhime
Original Assignee
Biogal Gyogyszergyar Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26866349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU45202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogal Gyogyszergyar Rt. filed Critical Biogal Gyogyszergyar Rt.
Publication of YU45202A publication Critical patent/YU45202A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Obezbedjeni su novi polimorfni oblici natrijum pravastatina. Svaki od novih oblika je dobijen selektivno kristalizacijom iz različitih sistema rastvarača, svaki sistem rastvarača ima protičku komponentu, i kontrolom stope kristalizacije putem temperature. Novi polimorfni oblici pogodni su za upotrebu kao aktivne supstance farmaceutskih oblika doza za redukciju nivoa serumskog holesterola u krvotoku.[New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream.
YU45202A 1999-12-14 2000-12-14 Novi oblici natrijum pravastatina YU45202A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17068599P 1999-12-14 1999-12-14
US19064900P 2000-03-20 2000-03-20

Publications (1)

Publication Number Publication Date
YU45202A true YU45202A (sh) 2005-11-28

Family

ID=26866349

Family Applications (1)

Application Number Title Priority Date Filing Date
YU45202A YU45202A (sh) 1999-12-14 2000-12-14 Novi oblici natrijum pravastatina

Country Status (15)

Country Link
US (3) US7001919B2 (sh)
EP (1) EP1242051A4 (sh)
JP (2) JP2003516959A (sh)
KR (1) KR20020062340A (sh)
CN (1) CN1434702A (sh)
AU (1) AU779306B2 (sh)
CA (1) CA2394200C (sh)
CZ (1) CZ20021998A3 (sh)
HK (1) HK1049441A1 (sh)
HU (1) HUP0204005A3 (sh)
IL (1) IL150187A0 (sh)
PL (1) PL364929A1 (sh)
SK (1) SK8312002A3 (sh)
WO (1) WO2001043723A1 (sh)
YU (1) YU45202A (sh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2394200C (en) * 1999-12-14 2006-10-03 Biogal Gyogyszergyar Rt. Novel forms of pravastatin sodium
ES2292721T3 (es) * 2001-03-27 2008-03-16 Dainippon Sumitomo Pharma Co., Ltd. Derivado de isoxazol cristalino y preparacion medica del mismo.
US20080242725A1 (en) * 2004-03-01 2008-10-02 Janez Kerc Pharmaceutical Composition
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
WO2006086680A1 (en) * 2005-02-09 2006-08-17 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Methods of making pravastatin sodium
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
CN101648867B (zh) * 2009-09-04 2012-07-11 天津大学 一种普伐他汀钠晶型及其制备方法和应用
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
WO2012085191A1 (en) 2010-12-23 2012-06-28 Dsm Sinochem Pharmaceuticals Netherlands B.V. Crystalline form of pravastatine and process for the preparation thereof
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN105949062B (zh) * 2016-06-24 2017-06-13 广东蓝宝制药有限公司 一种规模化制备普伐他汀钠d型晶体的工艺
CN111018714B (zh) * 2019-12-27 2020-09-04 广东蓝宝制药有限公司 一种获得高纯a晶型普伐他汀钠的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
EP0215665B1 (en) 1985-09-13 1991-11-21 Sankyo Company Limited Hydroxy-ml-236b derivatives, their preparation and use
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857522A (en) 1988-03-21 1989-08-15 E. R. Squibb & Sons, Inc. Derivatives of pravastatin for inhibiting cholesterol biosynthesis
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
NZ250609A (en) 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
IL112639A0 (en) 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
US5942423A (en) * 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
WO1998037220A1 (en) 1997-02-20 1998-08-27 Dsm N.V. Nitrogen feed in statin fermentation
KR100210482B1 (ko) * 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
WO1999010499A1 (en) 1997-08-22 1999-03-04 Dsm N.V. Statin production by fermentation
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20072A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
WO2000033821A1 (en) * 1998-12-07 2000-06-15 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
CN1260344C (zh) 1999-02-03 2006-06-21 药物研究所有限公司 培养物
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
EP1265604B1 (en) 1999-11-30 2006-10-18 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for recovering statin compounds from a fermentation broth
CA2394200C (en) * 1999-12-14 2006-10-03 Biogal Gyogyszergyar Rt. Novel forms of pravastatin sodium
JP3737801B2 (ja) 2000-10-05 2006-01-25 テバ ジョジセルジャール レースベニュタールシャシャーグ プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
DE10209305A1 (de) 2001-04-30 2002-10-31 Basf Ag Thermische Spaltung von Allophanaten

Also Published As

Publication number Publication date
AU779306B2 (en) 2005-01-13
WO2001043723A1 (en) 2001-06-21
US7262218B2 (en) 2007-08-28
KR20020062340A (ko) 2002-07-25
HUP0204005A2 (hu) 2003-03-28
EP1242051A1 (en) 2002-09-25
CA2394200C (en) 2006-10-03
PL364929A1 (en) 2004-12-27
CN1434702A (zh) 2003-08-06
US20050288370A1 (en) 2005-12-29
HK1049441A1 (zh) 2003-05-16
JP2003516959A (ja) 2003-05-20
EP1242051A4 (en) 2004-05-12
CZ20021998A3 (cs) 2003-02-12
IL150187A0 (en) 2002-12-01
AU2098701A (en) 2001-06-25
JP2005120105A (ja) 2005-05-12
CA2394200A1 (en) 2001-06-21
US20070197633A1 (en) 2007-08-23
SK8312002A3 (en) 2003-05-02
US20010041809A1 (en) 2001-11-15
HUP0204005A3 (en) 2003-05-28
US7001919B2 (en) 2006-02-21

Similar Documents

Publication Publication Date Title
YU45202A (sh) Novi oblici natrijum pravastatina
AU6075198A (en) Drug delivery system for two or more active substances
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
AU8009998A (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
CA2445276A1 (en) Aripiprazole oral solution
ZA962536B (en) Pharmaceutical composition for transdermal administration.
MA25493A1 (fr) Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
PT1441705E (pt) Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos
AU1632601A (en) System and method for pharmacy administration
AU2002227389A1 (en) System for vertical, horizontal and lateral movement of a patient
IT1307266B1 (it) Apparecchio per infusione di farmaci.
WO2001041737A3 (en) Solid oral dosage form
IL148870A0 (en) 2'-substituted 1, 1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds
ZA985406B (en) Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical preparations containing these compounds.
HK1015789A1 (en) Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use.
DE69908399D1 (de) Arzneistoffabgabesystem, insbesondere zur verabreichung von androgenen
NO307048B1 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
DK0825865T3 (da) Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat
EP1523978A3 (en) Crystalline forms of pravastatin sodium
AU4331700A (en) Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives
IL148573A0 (en) New pyrimidine -2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
NO975371D0 (no) Farmasöytisk sammensetning fremstilt ved tilföring av en smakstilsetningsbærer til et medikament
MY115795A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
EP0583606A3 (en) New cardioactive hydrazono-5-beta, 14-beta-androstanes, process for their preparation and the pharmaceutical compositions containing them.